HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wella AG

This article was originally published in The Rose Sheet

Executive Summary

Slow sales growth anticipated for 1998, missing internal targets by 5% due to the international financial crisis, the firm announced Sept. 28. Unexpected developments in Russia and Asia, particularly Japan, as well as weak performances in Australia and New Zealand contributed to the slowdown, the company explained. Wella Japan is expected to post weak sales for the first time. The firm noted a drop in Japanese consumer demand and the decline in Wella sales in the country had been worsened by the 12% decrease in the value of the yen. Despite the negative currency effects on Wella's 1998 business results, the company anticipates 1999 currency factors are likely to have a positive impact on the company's performance and said its internal targets will be back on track

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel